Tata Motors owned UK’s largest car producer, Jaguar Land Rover (JLR) is on its way to make an announcement to axe thousands of jobs as the auto giant faces significant fall in demand in China and a decline in diesel car sale in Europe, media reports said on Thursday (10).
The auto firm has prepared plans to reduce costs and raise cash flows by £2.5 billion. The plans include reducing employment costs and levels, Reuters reported citing a source who disclosed the plans on condition of anonymity.
There may be substantial job losses impacting managerial, sales, design, and other departments. However, the production-line staff will not be affected at this stage.
The firm produces a major proportion of its cars in Britain than any other major or medium sized car company. The automaker has also spent millions of pounds to prepare for Brexit, in the case of there are tariffs.
The automaker swung to a loss of £354 million during April to September period and had cut around 1000 roles in the UK in 2018. The firm had shut its Solihull plant for 14 days and announced a three-day week at its Castle Bromwich site.
JLR which has a staff strength of 40, 000 in the UK and had been adding new employees to its workforce at new plants in China and Slovakia in recent years.
Sales in China during July and September fell by 44 per cent, the biggest fall for the automaker.
Diesel accounts for 90 per cent of the firm's British sales and 45 per cent of global demand, the company said last year, as demand in the segment tumbles following new levies in the wake of the 2015 Volkswagen emissions cheating scandal.
Diesel accounts for 90 per cent of the automaker’s sales in Britain and 45 per cent of world demand, according to the company.
Akin other auto manufacturers, the JLR could see its three British car plans grind to a halt within 80 days if lawmakers reject a deal by British prime minister Theresa May next week, leading to tariffs and customs checks after a no-deal outcome.
UK life sciences sector contributed £17.6bn GVA in 2021 and supports 126,000 high-skilled jobs.
Inward life sciences FDI fell by 58 per cent from £1,897m in 2021 to £795m in 2023.
Experts warn NHS underinvestment and NICE pricing rules are deterring innovation and patient access.
Investment gap
Britain is seeking to attract new pharmaceutical investment as part of its plan to strengthen the life sciences sector, Chancellor Rachel Reeves said during meetings in Washington this week. “We do need to make sure that we are an attractive place for pharmaceuticals, and that includes on pricing, but in return for that, we want to see more investment flow to Britain,” Reeves told reporters.
Recent ABPI report, ‘Creating the conditions for investment and growth’, The UK’s pharmaceutical industry is integral to both the country’s health and growth missions, contributing £17.6 billion in direct gross value added (GVA) annually and supporting 126,000 high-skilled jobs across the nation. It also invests more in research and development (R&D) than any other sector. Yet inward life sciences foreign direct investment (FDI) fell by 58per cent, from £1,897 million in 2021 to £795 million in 2023, while pharmaceutical R&D investment in the UK lagged behind global growth trends, costing an estimated £1.3 billion in lost investment in 2023 alone.
Richard Torbett, ABPI Chief Executive, noted “The UK can lead globally in medicines and vaccines, unlocking billions in R&D investment and improving patient access but only if barriers are removed and innovation rewarded.”
The UK invests just 9% of healthcare spending in medicines, compared with 17% in Spain, and only 37% of new medicines are made fully available for their licensed indications, compared to 90% in Germany.
Expert reviews
Shailesh Solanki, executive editor of Pharmacy Business, pointed that “The government’s own review shows the sector is underfunded by about £2 billion per year. To make transformation a reality, this gap must be closed with clear plans for investment in people, premises and technology.”
The National Institute for Health and Care Excellence (NICE) cost-effectiveness threshold £20,000 to £30,000 per Quality-Adjusted Life Year (QALY) — has remained unchanged for over two decades, delaying or deterring new medicine launches. Raising it is viewed as vital to attracting foreign investment, expanding patient access, and maintaining the UK’s global standing in life sciences.
Guy Oliver, General Manager for Bristol Myers Squibb UK and Ireland, noted that " the current VPAG rate is leaving UK patients behind other countries, forcing cuts to NHS partnerships, clinical trials, and workforce despite government growth ambitions".
Reeves’ push for reform, supported by the ABPI’s Competitiveness Framework, underlines Britain’s intent to stay a leading hub for pharmaceutical innovation while ensuring NHS patients will gain faster access to new treatments.
By clicking the 'Subscribe’, you agree to receive our newsletter, marketing communications and industry
partners/sponsors sharing promotional product information via email and print communication from Garavi Gujarat
Publications Ltd and subsidiaries. You have the right to withdraw your consent at any time by clicking the
unsubscribe link in our emails. We will use your email address to personalize our communications and send you
relevant offers. Your data will be stored up to 30 days after unsubscribing.
Contact us at data@amg.biz to see how we manage and store your data.